Theriva Sells Ribaxamase Assets to Biossil for $350,000 Upfront
Theriva Biologics completed the sale of Ribaxamase-related and certain SYN-006 assets to Biossil Labs for $350,000 upfront, plus potential milestone, royalty and license payments. A related amendment requires Theriva to pay PREV ABR $140,000 at closing and share certain future payments.
Theriva Biologics completed the sale of assets related to Ribaxamase and certain SYN-006 assets to Biossil Labs for $350,000 upfront, with potential additional milestone, royalty and license payments. In a related amendment, Theriva agreed to pay PREV ABR $140,000 at closing and share certain futur…